



NEW VALIDATED METHOD FOR THE ESTIMATION OF REMOGLIFLOZIN IN PHARMACEUTICAL DOSAGE FORM USING RP-HPLC

^{1,*} Kokkeragadda Akhila, ² Dr. Srinivasa Rao N

^{1, 2}Department of pharmacy, Vikas College of pharmacy, Vissannapeta, AP.
akhimaggie32@gmail.com

Abstract

The present paper describes a simple, accurate and precise reversed phase High Performance Liquid Chromatography (HPLC) method for rapid and simultaneous quantification of Remogliflozin. The chromatographic separation was achieved on X-Bridge Phynol (150x4.6mm, 3.5µm) column. Mobile phase contained a mixture of 0.1% Ortho Phosphoric Acid and Acetonitrile in the ratio of 80:20 v/v, flow rate 1.0ml/min and UV detection at 249nm. The proposed method shows a good linearity in the concentration range of 75-450µg/ml of Remogliflozin under optimized conditions. Precision and recovery study results are in between 98-102%. In the entire robustness conditions %RSD is below 2.0%. Degradation has minimum effect in stress condition and solutions are stable up to 24hrs. This method is validated for different parameters like Precision, linearity, accuracy, limit of detection (LOD), limit of quantification (LOQ), ruggedness, robustness and forced degradation study were determined according to the ICH Q2B guidelines. All the parameters of validation were found to be within the acceptance range of ICH guidelines.

Key words: RP-HPLC, Validation, Remogliflozin.

INTRODUCTION

Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin [1, 2] class for the treatment of non-alcoholic steatohepatitis ("NASH") [3, 4] and type 2 diabetes [5, 6]. Remogliflozin etabonate was shown to enhance urinary glucose excretion [7] in rodents [8] and humans. Early studies in diabetics [9, 10] improved plasma glucose levels. A pair of 12-week phase 2b randomized clinical trials of diabetics published in 2015, found reductions in glycated hemoglobin [11, 12] and that it was generally well tolerated. Remogliflozin etabonate is a pro-drug [13, 14] of remogliflozin. Remogliflozin inhibits the sodium-glucose transport proteins (SGLT) [15, 16], which are responsible for glucose re-absorption in the kidney [17, 18]. Blocking this transporter causes blood glucose to be eliminated through the urine. Remogliflozin is selective for SGLT2.




Fig.1: Remogliflozin etabonate

MATERIALS AND METHODS**Chemicals**

Acetonitrile, Ortho Phosphoric acid (OPA) and water (HPLC grade), were purchased from Merck (India) Ltd. Worli, Mumbai, India. All APIs of Remogliflozin as reference standards were procured from Torrent Pharma, Ahmadabad.

Equipment

Waters alliance -2695 chromatographic system consisting of quaternary pump, PDA detector-2996 and chromatographic software Empower-2.0 was used.

Chromatographic conditions

Chromatographic separation was carried out in isocratic mode at room temperature using X-Bridge C₈ (150x4.6mm, 3.5 μ) column. The mixture of Hexane Sulphonic acid of pH=5 adjusted with OPA: Acetonitrile 80:20 v/v at a flow rate of 1.0ml/min was used as a mobile phase. The injection volume was 10 μ l and eluent was monitored at 275nm using PDA detector. The run time was 4min.

Selection of wavelength

The absorption spectra of solution of Remogliflozin are scanned over the range of 75-450nm by using PDA detector and the spectra was recorded. The spectrum was shown in fig.3.




Fig. 2: PDA Spectrum of Remogliflozin

Preparation of Standard solution:

Accurately weigh and transfer 30 mg of Remogliflozin working standard into a 10 ml clean dry volumetric flask add Diluent and sonicate to dissolve it completely and make volume up to the mark with the same solvent. (Stock solution)

Further pipette 1 ml of the above stock solutions into a 10 ml volumetric flask and dilute up to the mark with diluent. (300ppm of Remogliflozin)

Preparation of Sample solution

Accurately weighed and transfer equivalent to 193mg of Remogliflozin sample into a 10mL clean dry volumetric flask add Diluent and sonicate it up to 30 min to dissolve, and centrifuge for 30min. to dissolve it completely and make volume up to the mark with the same solvent. Then it is filtered through 0.45 micron Injection filter. (Stock solution). Further pipette 1 ml of the above stock solutions into a 10ml volumetric flask and dilute up to the mark with diluent. (300ppm of Remogliflozin)

Validation Procedure

The analytical method was validated as per ICH Q2 (R₁) guidelines for the parameters like system Precision, specificity, accuracy, precision, linearity, robustness, limit of detection (LOD), limit of quantification (LOQ) and forced degradation.

System Suitability

System suitability parameters were measured to verify the system performance. The parameters including USP plate count, USP tailing and % RSD are calculated and found to be within the limits.

Specificity

Specificity is the ability to assess unequivocally the analyte in the presence of other components, which may be expected to be present in the sample and standard solution. It was checked by examining the chromatograms of blank samples and samples spiked with Remogliflozin.

Accuracy

Accuracy is the closeness of the test results obtained by the method to the true value. It was assessed by the recovery studies at three different concentration levels. In each level, a minimum of three injections were given and amount of the drug present, percentage recovery and related standard deviation were calculated.

Precision

Precision of an analytical method is the degree of agreement among individual test results. It was studied by analysis of multiple sampling of homogeneous sample. The precision of the present method was assessed in terms of repeatability, intra-day and inter day variations. It was checked by analyzing the samples at different time intervals of the same day as well as on different days.

Linearity and range

Linearity of an analytical method is its ability to obtain results directly proportional to the concentration of the analyte in the sample within a definite range. The six series of standard solutions were selected for assessing linearity range. The calibration curve was plotted using peak area versus concentration of the standard solution and the regression equations were calculated. The least squares method was used to calculate the slope, intercept and correlation coefficient.

LOD and LOQ

LOD is the lowest amount of analyte in a sample that can be detected while LOQ is the lowest amount of analyte in a sample that can be determined with acceptable precision and accuracy. LOD and LOQ were separately determined based on the calibration curves. The LOD and LOQ for Remogliflozin and dapsons were determined by injecting progressively low concentrations of standard solutions using the developed RP-HPLC method. The LOD and LOQ for calculated as $3.3s/n$ and $10s/n$ respectively as per ICH guidelines where s/n indicates signal-to-noise ratio.

Stress Degradation

Stress degradation should be no interference between the peaks obtained for the chromatogram of forced degradation preparations. Stress degradation studies were performed as per ICH guidelines Q₁A (R₂). The degradation peaks should be well separated from each other and the resolution between the peaks should be at least 1.0 and the peak purity of the principle peaks shall pass. Forced degradation studies were performed by different types of stress conditions to obtain the degradation of about 20%.

Robustness

The robustness of an analytical procedure is a measure of its ability to remain unaffected by small but deliberate variations in method parameters and provides an indication of its reliability during normal usage. Robustness study was performed by injecting standard solution into the HPLC system and altered chromatographic conditions such as flow rate (± 0.2), organic content in the mobile phase ($\pm 10\%$). The separation factor, retention time and peak asymmetry were calculated by determining the effect of the modified parameters.

RESULTS AND DISCUSSION

Method Validation

In this method system suitability, linearity, precision, accuracy, LOD, LOQ, robustness, forced degradation are validated for the selected drugs Remogliflozin drugs. The proposed method having standard solution and sample solution chromatograms are shown.




Fig. 3: Chromatogram of standard




Fig. 4: Chromatogram of sample

System suitability

The HPLC system was stabilized for 60min to get a stable baseline. Six replicate injections of the standard solution containing $300\mu\text{g/ml}$ of Remogliflozin were assessed to check the system suitability. The number of theoretical plate count for Remogliflozin were 2266 respectively. Tailing factor for Remogliflozin were 1.12 respectively. All the parameters were found to be within limit.

Linearity

Linearity of the method was evaluated by preparing a standard solution containing 300µg/ml of Remogliflozin. Sequential dilutions were performed to the given solutions at 25, 50, 75, 100, 125 and 150% of the target concentrations. These were injected and the peak areas are used to plot calibration curves against the concentration. The correlation coefficient values of these analytes were 0.9993. The results were shown in table 1.

Table 1: Linearity study results

Analyte	Linearity range	Equation of calibration curve	Correlation coefficient
Remogliflozin	75-450µg/ml	$y = 9950.89x + 11664.57$	0.9993




Fig. 5: Linearity plot for Remogliflozin

LOD and LOQ

LOD and LOQ minimum concentration level at which the analyte can be reliably detected, quantified by using the standard formulas. LOD values for Remogliflozin were 0.01µg/ml. LOQ values for Remogliflozin were 0.1µg/ml.

Precision

Method precision was investigated by the analysis of six separately prepared samples of the same batch. From these six separate samples solution was injected and the peak areas obtained used to calculate mean and percentage RSD values. The present method was found to be precise as %RSD of the less than 2.0%. The results are given in table 2.

Table 2: Method Precision results

Analyte	Amount present	% RSD
Remogliflozin	10	0.91

Accuracy

Accuracy was determined by recovery studies which were carried out in three different concentration levels (50%, 100% and 150%). APIs with concentration 150,300 and 450µg/ml of Remogliflozin were prepared. As per the test method the test solution was injected to three preparations each spike level and the assay was performed. The percentage recovery values were found to be in the range of 98-102%. The results are given in table 3.

Table 3: Accuracy (recovery) study results

% of target concentration	Remogliflozin (% Recovery)
50	98.5
100	99.2
150	101.3
Mean (% Recovery)	99.7

Ruggedness

Ruggedness of the method was studied and showed that chromatographic patterns did not significantly change when different HPLC system, analyst, column. The value of percentage of RSD was below 2% exhibits the ruggedness of the developed method.

Robustness

Robustness of the method was found to be %RSD should be less than 2%. Slightly variations were done in the optimized method parameters like flow rate ($\pm 20\%$), Organic content in mobile phase ($\pm 10\%$). The results are given in table 4.

Table 4: Robustness results

Drug Name	Flow Plus (1.2ml/min)	Flow Minus (0.8ml/min)	Organic Plus (18:82)	Organic Minus (22:78)
	%RSD			
Remogliflozin	0.55	0.74	0.67	0.73

Forced Degradation

Forced degradation conditions such as acidic, basic, oxidation, thermal and water stress were attempted as per ICH Q1A (R2). The effect of assay on their results are shown below table 5.

Table 6: Forced Degradation results

Degradation	Remogliflozin (% Degradation)
Acid	12.5
Alkali	11.8
Peroxide	14.6
Reduction	17
Thermal	0.7

CONCLUSION

This method described the quantification of Remogliflozin in bulk and pharmaceutical formulation as per ICH guidelines. The developed method was found to be accurate, precise, linear and reliable. The advantage lies in the simplicity of sample preparation and the less expensive reagents were used. In addition Remogliflozin is eluted within 4mins. The proposed HPLC conditions ensure sufficient resolution and the precise quantification of the compounds. Statistical analysis of the experimental result indicates that the precision and reproducibility data are satisfactory. The developed chromatographic method can be effectively applied for routine analysis in drug research.

REFERENCES

1. Nauck, Michael. Update on developments with SGLT2 inhibitors in the management of type 2 diabetes. *Drug Design, Development and Therapy*. 2014, 8: 1335–80.
2. Nashawi, Mouhamed, Sheikh, Omar, Battisha, Ayman, Ghali, Abdullah, Chilton, Robert. Neural tone and cardio-renal outcomes in patients with type 2 diabetes mellitus. a review of the literature with a focus on SGLT2 inhibitors. *Heart Failure Reviews*. May 2021, 26 (3): 643–652.
3. Mummadi RR, Kasturi KS, Chennareddygar S, Sood GK. Effect of bariatric surgery on nonalcoholic fatty liver disease. systematic review and meta-analysis. *Clinical Gastroenterology and Hepatology*. December 2008, 6 (12): 1396–402.
4. Liangpunsakul S, Chalasani N. Is hypothyroidism a risk factor for non-alcoholic steatohepatitis. *Journal of Clinical Gastroenterology*. October 2003, 37 (4): 340–3.
5. Thomas DE, Elliott EJ, Naughton GA. Exercise for type 2 diabetes mellitus. *The Cochrane Database of Systematic Reviews* (3): CD002968. July 2006.
6. Nieto-Martínez R, González-Rivas JP, Medina-Inojosa JR, Florez H. Are Eating Disorders Risk Factors for Type 2 Diabetes? A Systematic Review and Meta-analysis. *Current Diabetes Reports (Systematic review and meta-analysis)*. 22 November 2017, 17 (12): 138.
7. Weiner ID, Mitch WE, Sands JM. Urea and Ammonia Metabolism and the Control of Renal Nitrogen Excretion. *Clinical Journal of the American Society of Nephrology*. August 2015, 10 (8): 1444–58.
8. Ancillotto, Leonardo, Sozio, Giulia, Mortelliti, Alessio, Russo, Danilo. Ultrasonic communication in Gliridae (Rodentia): the hazel dormouse (*Muscardinus avellanarius*) as a case study. *Bioacoustics*. 2014, 23 (2): 129–141.
9. Saedi E, Gheini MR, Faiz F, Arami MA. Diabetes mellitus and cognitive impairments. *World Journal of Diabetes*. September 2016, 7 (17): 412–422.
10. Carris NW, Magness RR, Labovitz AJ. Prevention of Diabetes Mellitus in Patients With Prediabetes. *The American Journal of Cardiology*. February 2019, 123 (3): 507–512.
11. Oliwia Witczak, Trine B. Haugen. Glycated or glycosylated?. *Journal of the Norwegian Medical Association*. 25 November 2014, 134 (22): 2179.
12. Saleh, Jumana. Glycated hemoglobin and its spinoffs: Cardiovascular disease markers or risk factors?. *World Journal of Cardiology*. 2015-08-26, 7 (8): 449–53.
13. Rautio J, Meanwell NA, Di L, Hageman MJ. The expanding role of prodrugs in contemporary drug design and development. *Nature Reviews. Drug Discovery*. August 2018, 17 (8): 559–587.
14. Stella VJ, Charman WN, Naringrekar VH. Prodrugs. Do they have advantages in clinical practice?. *Drugs*. May 1985, 29 (5): 455–73.
15. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. *Pflügers Archiv*. February 2004, 447 (5): 510–8.
16. Wright EM. Renal Na(+)-glucose cotransporters. *American Journal of Physiology. Renal Physiology*. January 2001, 280 (1): F10–8.
17. Content initially copied from: Hansen, Kristoffer, Nielsen, Michael, Ewertsen, Caroline. Ultrasonography of the Kidney: A Pictorial Review. *Diagnostics*. 2015, 6 (1): 2.
18. Al-kahtani M A, Zuleta C, Caviedes-Vidal E, Garland Jr T. Kidney mass and relative medullary thickness of rodents in relation to habitat, body size, and phylogeny (PDF). *Physiological and Biochemical Zoology*. 2004, 77 (3): 346–365.